PMID- 31109967 OWN - NLM STAT- MEDLINE DCOM- 20200303 LR - 20200303 IS - 1470-8736 (Electronic) IS - 0143-5221 (Linking) VI - 133 IP - 10 DP - 2019 May 31 TI - Hsa_circ_0009361 acts as the sponge of miR-582 to suppress colorectal cancer progression by regulating APC2 expression. PG - 1197-1213 LID - 10.1042/CS20190286 [doi] AB - Circular RNA (circRNA) plays an important role in the development of human malignant tumors. Recently, an increasing number of circRNAs have been identified and investigated in various tumors. However, the expression pattern and biological function of circRNAs in colorectal cancer (CRC) still remain largely unexplored. In the present study, hsa_circ_0009361 was significantly down-regulated in CRC tissues and cells. Low expression level of hsa_circ_0009361 promoted the proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion of CRC cells. Hsa_circ_0009361 was identified as the sponge of miR-582 by fluorescence in situ hybridization (FISH), RNA immunoprecipitation (RIP), and luciferase reporter assays. Overexpression of hsa_circ_0009361 up-regulated the expression of adenomatous polyposis coli 2 (APC2) and inhibited the activity of the Wnt/beta-catenin pathway by competitively combining with miR-582. Exogenous miR-582 and APC2 interventions could reverse the multiple biological functions mediated by hsa_circ_0009361 in CRC cells. In vivo experiments also confirmed that hsa_circ_0009361 inhibited the growth and metastasis of CRC. Hsa_circ_0009361 acted as a tumor suppressive sponge of miR-582, which could up-regulate the expression of APC2, inhibit the Wnt/beta-catenin signaling, and suppress the growth and metastasis of CRC. Collectively, the hsa_circ_0009361/miR-582/APC2 network could be employed as a potential therapeutic target for CRC patients. CI - (c) 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society. FAU - Geng, Yiting AU - Geng Y AD - Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. FAU - Zheng, Xiao AU - Zheng X AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. AD - Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. FAU - Hu, Wenwei AU - Hu W AD - Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. FAU - Wang, Qi AU - Wang Q AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. AD - Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. FAU - Xu, Yanjie AU - Xu Y AD - Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. FAU - He, Wenting AU - He W AD - Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. FAU - Wu, Chen AU - Wu C AD - Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. FAU - Zhu, Danxia AU - Zhu D AD - Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. FAU - Wu, Changping AU - Wu C AUID- ORCID: 0000-0003-1170-0857 AD - Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China wcpjjt@163.com jiangjingting@suda.edu.cn. AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. FAU - Jiang, Jingting AU - Jiang J AD - Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou 213003, People's Republic of China wcpjjt@163.com jiangjingting@suda.edu.cn. AD - Institute of Cell Therapy, Soochow University, Changzhou 213003, People's Republic of China. AD - Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou 213003, Jiangsu, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190530 PL - England TA - Clin Sci (Lond) JT - Clinical science (London, England : 1979) JID - 7905731 RN - 0 (APC2 protein, human) RN - 0 (Cytoskeletal Proteins) RN - 0 (MIRN582 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (RNA, Circular) SB - IM MH - Cell Line, Tumor MH - Colorectal Neoplasms/*metabolism MH - Cytoskeletal Proteins/*metabolism MH - Humans MH - MicroRNAs/*metabolism MH - Neoplasm Metastasis MH - RNA, Circular/*metabolism MH - Wnt Signaling Pathway OTO - NOTNLM OT - APC2 OT - Colorectal cancer OT - EMT OT - Hsa_circ_0009361 OT - ceRNA OT - miR-582 EDAT- 2019/05/22 06:00 MHDA- 2020/03/04 06:00 CRDT- 2019/05/22 06:00 PHST- 2019/03/18 00:00 [received] PHST- 2019/05/15 00:00 [revised] PHST- 2019/05/20 00:00 [accepted] PHST- 2019/05/22 06:00 [pubmed] PHST- 2020/03/04 06:00 [medline] PHST- 2019/05/22 06:00 [entrez] AID - CS20190286 [pii] AID - 10.1042/CS20190286 [doi] PST - epublish SO - Clin Sci (Lond). 2019 May 30;133(10):1197-1213. doi: 10.1042/CS20190286. Print 2019 May 31.